美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Astellas Pharma, Inc.

9.28

+0.15001.64%

成交量：41.45萬

成交額：385.46萬

市值：172.77億

市盈率：124.81

高：9.35

開：9.11

低：9.11

收：9.13

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

美國OTC市場安斯泰萊製藥盤中異動快速跳水5.99%

美國OTC市場安斯泰萊製藥盤中異動股價大跌5.79%

中國國家藥品監督管理局批准備思復（維恩妥尤單抗）聯合可瑞達（帕博利珠單抗）用於治療晚期膀胱癌

中國國家藥品監督管理局批准威絡益（佐妥昔單抗）一線治療晚期胃或胃食管交界處腺癌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ALPMY"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":9.28,"timestamp":1744747200000,"preClose":9.13,"halted":0,"volume":414510,"delay":15,"floatShares":1731101601,"shares":1861787075,"eps":0.074352,"marketStatus":"盤前交易","change":0.15,"latestTime":"04-15 16:00:00 EDT 延時","open":9.11,"high":9.35,"low":9.11,"amount":3854583.5128999976,"amplitude":0.026287,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1744810200000},"marketStatusCode":1,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":9.28,"volumeRatio":0.6104676851738422},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1731101601,"roa":"3.67%","roe":"-3.83%","lyrEps":0.062841,"volumeRatio":0.6104676851738422,"shares":1861787075,"dividePrice":0.50436,"high":9.35,"amplitude":0.026287,"preClose":9.13,"low":9.11,"week52Low":8.37,"pbRate":"1.65","psRate":"1.32","week52High":13.14,"institutionHeld":0,"latestPrice":9.28,"eps":0.074352,"divideRate":0.054349,"volume":414510,"delay":15,"ttmEps":0.074352,"open":9.11,"prevYearClose":9.66,"prevWeekClose":8.88,"prevMonthClose":9.66,"prevQuarterClose":9.66,"fiveDayClose":8.99,"twentyDayClose":9.963,"sixtyDayClose":9.54,"earningDate":1745424000000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALPMY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526851603","title":"美國OTC市場安斯泰萊製藥盤中異動 快速跳水5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526851603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526851603?lang=zh_tw&edition=fundamental","pubTime":"2025-04-11 00:38","pubTimestamp":1744303139,"startTime":"0","endTime":"0","summary":"北京时间2025年04月11日00时38分，美国OTC市场安斯泰莱制药股票出现异动，股价快速下挫5.99%。截至发稿，该股报8.47美元/股，成交量28.3042万股，换手率0.02%，振幅8.32%。机构评级方面，在所有12家参与评级的机构中，33%的券商给予买入建议，58%的券商给予持有建议，9%的券商给予卖出建议。美国OTC市场安斯泰莱制药股票所在的制药行业中，整体跌幅为4.41%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250411003859a4552562&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250411003859a4552562&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALPMY"],"gpt_icon":0},{"id":"2508412971","title":"美國OTC市場安斯泰萊製藥盤中異動 股價大跌5.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508412971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508412971?lang=zh_tw&edition=fundamental","pubTime":"2025-02-03 22:46","pubTimestamp":1738593977,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时46分，美国OTC市场安斯泰莱制药股票出现波动，股价快速下挫5.79%。截至发稿，该股报9.12美元/股，成交量7406股，换手率0.00%，振幅5.99%。机构评级方面，在所有14家参与评级的机构中，43%的券商给予买入建议，50%的券商给予持有建议，7%的券商给予卖出建议。美国OTC市场安斯泰莱制药股票所在的制药行业中，整体涨幅为0.08%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224617abc10ae8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224617abc10ae8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALPMY"],"gpt_icon":0},{"id":"2501277310","title":"中國國家藥品監督管理局批准備思復（維恩妥尤單抗）聯合可瑞達（帕博利珠單抗）用於治療晚期膀胱癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2501277310","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501277310?lang=zh_tw&edition=fundamental","pubTime":"2025-01-08 16:05","pubTimestamp":1736323500,"startTime":"0","endTime":"0","summary":"EV-302试验中国主要研究者、北京大学肿瘤医院泌尿肿瘤暨黑色素瘤肉瘤内科主任、中国临床肿瘤学会副理事长兼秘书长郭军教授 \"近日NMPA批准的维恩妥尤单抗联合帕博利珠单抗的治疗组合，是国内获批的首个针对晚期膀胱癌患者的非铂化疗的治疗方案，可用于一线治疗。这次批准维恩妥尤单抗联合帕博利珠单抗的治疗方案，标志着我们再一次为中国患者带来了创新治疗选择。患者随机接受维恩妥尤单抗与帕博利珠单抗联合用药治疗或含铂化疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4591653_ZH91653_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1037948541.HKD","LU0320765489.SGD","LU0006306889.USD","SG9999014567.USD","IE00B4R5TH58.HKD","LU1989771016.USD","BK4559","LU0211331839.USD","LU0965509010.AUD","LU2106854487.HKD","LU2023250843.SGD","LU2089984988.USD","LU1699723380.USD","LU0289739699.SGD","LU1061106388.HKD","IE0009355771.USD","LU1057294990.SGD","ALPMY","IE00BN8TJ469.HKD","LU0234572021.USD","LU0070302665.USD","LU1941712264.USD","SG9999014542.SGD","LU0208291251.USD","LU0985320562.USD","LU0058720904.USD","LU0106261372.USD","IE00BLSP4452.SGD","BK4007","SG9999014575.USD","IE00B2B36J28.USD","LU1291159041.SGD","LU1917777945.USD","LU1941712348.USD","LU0122379950.USD","SG9999002224.SGD","LU1974910355.USD","LU1983299246.USD","IE00BJJMRZ35.SGD","MRK","IE0002141913.USD","BK4550","LU1116320737.USD","BK4534","LU1066051811.HKD","SGXZ57979304.SGD","IE00BSNM7G36.USD","LU0965508806.USD","LU1116320901.HKD","LU2361045086.USD"],"gpt_icon":0},{"id":"2501532952","title":"中國國家藥品監督管理局批准威絡益（佐妥昔單抗）一線治療晚期胃或胃食管交界處腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2501532952","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501532952?lang=zh_tw&edition=fundamental","pubTime":"2025-01-06 20:25","pubTimestamp":1736166300,"startTime":"0","endTime":"0","summary":"胃癌是中国与癌症相关死亡的第三大因素，2022年导致超过26万例死亡。近日国家药品监督管理局批准了佐妥昔单抗在中国上市，我们非常激动，它将为我国晚期胃癌患者增添一项宝贵且有效的一线治疗选择。SPOTLIGHT研究探索了佐妥昔单抗联合化疗方案在CLDN18.2阳性、HER2阴性晚期胃和胃食管交界处癌患者一线治疗中的疗效与安全性，在PFS与OS等关键指标上，呈现出统计学上的显著差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4589327_ZH89327_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2237443465.HKD","LU1066051811.HKD","LU1066053197.SGD","SG9999015978.USD","BK4525","SG9999015945.SGD","CDC","LU1823568750.SGD","SG9999002232.USD","BK4534","IE00BSNM7G36.USD","IE00B42XCP33.USD","LU2237443895.HKD","LU0942090050.USD","BK4515","SG9999015986.USD","IE00BGHQF631.EUR","BK4211","LU2506951958.HKD","BK4007","BK4533","LU1059921491.USD","LU1880398471.USD","LU1066051225.USD","BK4588","BK4097","BK4527","LU0823417653.USD","OS","LU0234570918.USD","IE00BVYPNV92.GBP","LU1244550221.USD","ALPMY","LU1235294995.USD","CSCO","LU1571399168.USD","LU1894683348.USD","PFS","LU2237443978.SGD","IE00BFXG1179.USD","LU2506952170.USD","IE00BVYPNW00.USD","LU2506952097.USD","LU0234572021.USD","SG9999001424.SGD","SG9999015952.SGD","LU2286300806.USD","SG9999001440.SGD","LU0950375773.USD","LU1880398554.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-01","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1698811200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1683000000000}}}